Bioabsorbable stent quo vadis: A case for nano-theranostics

Theranostics

Volumn 4, Issue 5, 2014, Pages 514-533

  Gundogan, Buket ^a,b   Tan, Aaron ^a,b   Farhatnia, Yasmin ^a   Alavijeh, Mohammad S ^c   Cui, Zhanfeng ^d   Seifalian, Alexander M ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Pharmidex Pharmaceutical Services Ltd   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bioabsorbable stent; Drug eluting stent; Nanotechnology; Theranostics

Indexed keywords

CERAMIDE; CITRIC ACID; DOXORUBICIN; EVEROLIMUS; HEAT SHOCK PROTEIN 70; IMATINIB; IRON; MAGNESIUM; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PITAVASTATIN; POLYGLACTIN; POLYLACTIC ACID; POLYLACTIDE; VASCULOTROPIN;

BARE METAL STENT; BIODEGRADABLE IMPLANT; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CLINICAL STUDY; COMPOSITE MATERIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEVICE APPROVAL; DEVICE SAFETY; DIAGNOSTIC IMAGING; DISSOLVABLE METALLIC STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG STRUCTURE; EQUIPMENT DESIGN; FLUORESCENCE MICROSCOPY; HUMAN; IN-STENT RESTENOSIS; LEG ISCHEMIA; MATERIAL COATING; METAL STENT; MICROSCOPY; MOLECULAR IMAGING; MOLECULAR PROBE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY;

BIOABSORBABLE STENT; DRUG-ELUTING STENT; NANOTECHNOLOGY; THERANOSTICS;

ABSORBABLE IMPLANTS; CORONARY DISEASE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; STENTS;

EID: 84902471681     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8137     Document Type: Review

References (127)

1. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010; 56: S1-42.
2. Rhee JW, Wu JC. Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med. 2013; 23: 39-45.
3. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978; 1: 263.
4. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987; 316: 701-706.
5. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991; 324: 13-17.
6. Brown DA, Lee EW, Loh CT, et al. A new wave in treatment of vascular occlusive disease: biodegradable stents-clinical experience and scientific principles. J Vasc Interv Radiol. 2009; 20: 315-324.
7. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006; 354: 483-495.
8. Karas SP, Gravanis MB, Santoian EC, et al. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol. 1992; 20: 467-474.
9. Gordon PC, Gibson CM, Cohen DJ, et al. Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment. J Am Coll Cardiol. 1993; 21: 1166-1174.
10. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996; 94: 1247-1254.
11. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011; 75: 1287-1296.
12. Holmes DR, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002; 106: 1243-1250.
13. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370: 937-948.
14. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 989-997.
15. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356: 998-1008.
16. Maisel WH. Unanswered questions--drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007; 356: 981-984.
17. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107: 38-42.
18. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773-1780.
19. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48: 2584-2591.
20. Kedia G, Lee MS. Stent thrombosis with drug-eluting stents: a re-examination of the evidence. Catheter Cardiovasc Interv. 2007; 69: 782-789.
21. Tan A, Farhatnia Y, de Mel A, et al. Inception to actualization: next generation coronary stent coatings incorporating nanotechnology. J Biotechnol. 2013; 164: 151-170.
22. Stack RS, Califf RM, Phillips HR, et al. Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol. 1988; 62: 3f-24f.
23. Saito S. New horizon of bioabsorbable stent. Catheter Cardiovasc Interv. 2005; 66: 595-596.
24. Colombo A, Karvouni E. Biodegradable stents: fulfilling the mission and stepping away. Circulation. 2000; 102: 371-373.
25. Erne P, Schier M, Resink TJ. The road to bioabsorbable stents: reaching clinical reality? Cardiovasc Intervent Radiol. 2006; 29: 11-16.
26. Peuster M, Wohlsein P, Brugmann M, et al. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart. 2001; 86: 563-569.
27. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010; 56: S43-78.
28. Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009; 2: 255-260.
29. Inoue M, Sasaki M, Katada Y, et al. Poly-(L-lactic acid) and citric acid-crosslinked gelatin composite matrices as a drug-eluting stent coating material with endothelialization, antithrombogenic, and drug release properties. J Biomed Mater Res A. 2013; 101: 2049-2057.
30. Stone P, Lord JW. An experimental study of the thrombogenic properties of magnesium and magnesium-aluminum wire in the dog's aorta. Surgery. 1951; 30: 987-993.
31. Jokerst JV, Gambhir SS. Molecular imaging with theranostic nanoparticles. Acc Chem Res. 2011; 44: 1050-1060.
32. Westedt U, Barbu-Tudoran L, Schaper AK, et al. Deposition of nanoparticles in the arterial vessel by porous balloon catheters: localization by confocal laser scanning microscopy and transmission electron microscopy. AAPS PharmSci. 2002; 4: E41.
33. Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res. 2011; 44: 999-1008.
34. Chen W, Cormode DP, Fayad ZA, et al. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 3: 146-161.
35. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation. 2002; 106: 1195-1198.
36. Zhang Y, Bourantas CV, Farooq V, et al. Bioresorbable scaffolds in the treatment of coronary artery disease. Med Devices (Auckl). 2013; 6: 37-48.
37. Waksman R, Pakala R, Baffour R, et al. Short-term effects of biocorrodible iron stents in porcine coronary arteries. J Interv Cardiol. 2008; 21: 15-20.
38. Hermawan H, Dube D, Mantovani D. Developments in metallic biodegradable stents. Acta Biomater. 2010; 6: 1693-1697.
39. Heublein B, Rohde R, Kaese V, et al. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003; 89: 651-656.
40. Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new opportunities. Int J Mol Sci. 2011; 12: 4250-4270.
41. Bosiers M, Peeters P, D'Archambeau O, et al. AMS INSIGHT-absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009 32: 424-435.
42. Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013; 381: 836-844.
43. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996; 94: 1690-1697.
44. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102: 399-404.
45. Tsuji T, Tamai H, Igaki K, et al. Biodegradable Polymeric Stents. Curr Interv Cardiol Rep. 2001; 3: 10-17.
46. Nishio S, Kosuga K, Igaki K, et al. Long-Term (> 10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012; 125: 2343-2353.
47. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373: 897-910.
48. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007; 69: 128-131.
49. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. Eurointervention. 2009; 5 (Suppl F): F15-22.
50. Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J Polym Sci B. 2011; 49: 832-864.
51. Pitt CG, Gratzl MM, Kimmel GL, et al. Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. Biomaterials. 1981; 2: 215-220.
52. Weir NA, Buchanan FJ, Orr JF, et al. Degradation of poly-L-lactide. Part 1: in vitro and in vivo physiological temperature degradation. Proc Inst Mech Eng H. 2004; 218: 307-319.
53. Weir NA, Buchanan FJ, Orr JF, et al. Degradation of poly-L-lactide. Part 2: increased temperature accelerated degradation. Proc Inst Mech Eng H. 2004; 218: 321-330.
54. Jukema JW, Ahmed TA, Verschuren JJ, et al. Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol. 2012; 9: 79-90.
55. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eurointervention. 2010; 6: 447-453.
56. Brugaletta S, Garcia-Garcia HM, Diletti R, et al. Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. Eurointervention. 2011; 6: 1110-1116.
57. Gomez-Lara J, Brugaletta S, Diletti R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J. 2011; 32: 294-304.
58. Gomez-Lara J, Brugaletta S, Farooq V, et al. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv. 2011; 4: 1271-1280.
59. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv. 2010; 3: 1190-1198.
60. Okamura T, Garg S, Gutierrez-Chico JL, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. Eurointervention. 2010; 5: 932-938.
61. Onuma Y, Serruys PW, Gomez J, et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv. 2011; 78: 3-12.
62. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Cathether Cardiovasc Interv. 2007; 70: 515-523.
63. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012; 221: 106-112.
64. Diletti R, Farooq V, Girasis C, et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart. 2013; 99: 98-105.
65. Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eurointervention. 2012; 7: 1060-1061.
66. Muramatsu T, Onuma Y, Garcia-Garcia HM, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013; 6: 247-257.
67. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371: 899-907.
68. Sarno G, Bruining N, Onuma Y, et al. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int J Cardiovasc Imaging. 2012; 28: 51-58.
69. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011; 58: 1578-1588.
70. Ding H, Wu F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics. 2012; 2: 1040-1053.
71. Nystrom AM, Wooley KL. The importance of chemistry in creating well-defined nanoscopic embedded therapeutics: devices capable of the dual functions of imaging and therapy. Acc Chem Res. 2011; 44: 969-978.
72. Binsalamah ZM, Paul A, Prakash S, et al. Nanomedicine in cardiovascular therapy: recent advancements. Expert Rev Cardiovasc Ther. 2012; 10: 805-815.
73. Huang G, Zhang C, Li S, et al. A Novel Strategy for Surface Modification of Superparamagnetic Iron Oxide Nanoparticles for Lung Cancer Imaging. J Mater Chem. 2009; 19: 6367-6372.
74. Lu J, Liong M, Zink JI, et al. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007; 3: 1341-1346.
75. Thomas CR, Ferris DP, Lee JH, et al. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J Am Chem Soc. 2010; 132: 10623-10625.
76. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003; 2: 347-360.
77. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-171.
78. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7: 771-782.
79. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001; 47: 113-131.
80. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 2006; 112: 630-648.
81. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998; 16: 2445-2451.
82. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004; 95: 1-8.
83. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15: 440-449.
84. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23: 7794-7803.
85. Chacko AM, Hood ED, Zern BJ, et al. Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation. Curr Opin Colloid Interface Sci. 2011; 16: 215-227.
86. Masuda S, Nakano K, Funakoshi K, et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J Atheroscler Thromb. 2011; 18: 1043-1053.
87. Yang J, Zeng Y, Zhang C, et al. The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. Biomaterials. 2013; 34: 1635-1643.
88. Jiang H, Zhang T, Sun X. Vascular endothelial growth factor gene delivery by magnetic DNA nanospheres ameliorates limb ischemia in rabbits. J Surg Res. 2005; 126: 48-54.
89. Bhargava B, Reddy NK, Karthikeyan G, et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv. 2006; 67: 698-702.
90. Uwatoku T, Shimokawa H, Abe K, et al. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res. 2003; 92: e62-69.
91. Banai S, Chorny M, Gertz SD, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials. 2005; 26: 451-461.
92. Golub JS, Kim YT, Duvall CL, et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol. 2010; 298: H1959-1965.
93. Oda S, Nagahama R, Nakano K, et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg. 2010; 52: 412-420.
94. Deshpande D, Devalapally H, Amiji M. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res. 2008; 25: 1936-1947.
95. Sawa Y, Morishita R, Suzuki K, et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation. 1997; 96: 280-284.
96. Suzuki K, Sawa Y, Kaneda Y, et al. In vivo gene transfection with heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat. J Clin Invest. 1997; 99: 1645-1650.
97. Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 2002; 106: 599-605.
98. Gutman D, Golomb G. Liposomal alendronate for the treatment of restenosis. J Control Release. 2012; 161: 619-627.
99. Pelisek J, Fuchs A, Engelmann MG, et al. Vascular endothelial growth factor response in porcine coronary and peripheral arteries using nonsurgical occlusion model, local delivery, and liposome-mediated gene transfer. Endothelium. 2003; 10: 247-255.
100. Lindner JR. Molecular imaging of cardiovascular disease with contrast-enhanced ultrasonography. Nat Rev Cardiol. 2009; 6: 475-481.
101. van der Hoeven BL, Schalij MJ, Delgado V. Multimodality imaging in interventional cardiology. Nat Rev Cardiol. 2012; 9: 333-346.
102. Wu C, Li F, Niu G, et al. PET imaging of inflammation biomarkers. Theranostics. 2013; 3: 448-466.
103. Lammers T, Kiessling F, Hennink WE, et al. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm. 2010; 7: 1899-1912.
104. Chen KJ, Wolahan SM, Wang H, et al. A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials. 2011; 32: 2160-2165.
105. Straathof R, Strijkers GJ, Nicolay K. Target-specific paramagnetic and superparamagnetic micelles for molecular MR imaging. Methods Mol Biol. 2011; 771: 691-715.
106. Ben-Dor I, Mahmoudi M, Pichard AD, et al. Optical coherence tomography: a new imaging modality for plaque characterization and stent implantation. J Interv Cardiol. 2011; 24: 184-192.
107. Yonetsu T, Bouma BE, Kato K, et al. Optical coherence tomography-15 years in cardiology. Circ J. 2013; 77: 1933-1940.
108. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003; 107: 2453-2458.
109. Chapon C, Franconi F, Lemaire L, et al. High field magnetic resonance imaging evaluation of superparamagnetic iron oxide nanoparticles in a permanent rat myocardial infarction. Invest Radiol. 2003; 38: 141-146.
110. Panizzi P, Nahrendorf M, Wildgruber M, et al. Oxazine conjugated nanoparticle detects in vivo hypochlorous acid and peroxynitrite generation. J Am Chem Soc. 2009; 131: 15739-15744.
111. Koch AM, Reynolds F, Kircher MF, et al. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem. 2003; 14: 1115-1121.
112. Farrar CT, Dai G, Novikov M, et al. Impact of field strength and iron oxide nanoparticle concentration on the linearity and diagnostic accuracy of off-resonance imaging. NMR Biomed. 2008; 21: 453-463.
113. Weissleder R, Lee AS, Khaw BA, et al. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology. 1992; 182: 381-385.
114. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001; 103: 415-22.
115. Kao CY, Hoffman EA, Beck KC, et al. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol. 2003; 10: 475-83.
116. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008; 3: 233-42.
117. Majmudar MD, Yoo J, Keliher EJ, et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res. 2013; 112: 755-761.
118. Hamoudeh M, Al Faraj A, Canet-Soulas E, et al. Elaboration of PLLA-based superparamagnetic nanoparticles: characterization, magnetic behaviour study and in vitro relaxivity evaluation. Int J Pharm. 2007; 338: 248-57.
119. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007; 369: 1869-75.
120. Uhrich KE, Cannizzaro SM, Langer RS, et al. Polymeric Systems for Controlled Drug Release. Chem Rev. 1999; 99: 3181-98.
121. Nakano K, Egashira K, Masuda S, et al. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv. 2009; 2: 277-83.
122. Cao W, Zhou J, Mann A, et al. Folate-functionalized unimolecular micelles based on a degradable amphiphilic dendrimer-like star polymer for cancer cell-targeted drug delivery. Biomacromolecules. 2011; 12: 2697-707.
123. Maraloiu VA, Hamoudeh M, Fessi H, et al. Study of magnetic nanovectors by Wet-STEM, a new ESEM mode in transmission. J Colloid Interface Sci. 2010; 352: 386-92.
124. Sharif F, Hynes SO, McCullagh KJ, et al. Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model. Gene Ther. 2012; 19: 321-8.
125. Magrez A, Kasas S, Salicio V, et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett. 2006; 6: 1121-5.
126. Ghosh M, Chakraborty A, Mukherjee A. Cytotoxic, genotoxic and the hemolytic effect of titanium dioxide (TiO2 ) nanoparticles on human erythrocyte and lymphocyte cells in vitro. J Appl Toxicol. 2013; 33: 1097-110.
127. Yu T, Malugin A, Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano. 2011; 5: 5717-28.